Is Cabazitaxel A Chemotherapy
Cabazitaxel powder, or Jevtana, XRP6258, is a chemotherapy drug classified as a taxane. It is primarily indicated for the treatment of patients with metastatic castration-resistant prostate disease (mCRPC) who have previously received docetaxel-based chemotherapy. Metastatic castration-resistant prostate disease (mCRPC) is an advanced stage of prostate disease in which diseased cells have spread to other parts of the body, such as bones or other organs. "Castration resistance" means that diseased cells no longer respond to hormonal treatments, such as castration. That means that patients with mCRPC have limited treatment options and often need to use other treatments, such as chemotherapy, targeted therapy, or radiotherapy.
XRP6258 demonstrated efficacy in mCRPC in the pivotal Phase III TROPIC trial, which showed that it prolonged overall survival compared with mitoxantrone in patients previously treated with docetaxel. This critical trial's results support its approval as a valuable treatment for mCRPC patients whose disease has advanced despite previous chemotherapy. Studies investigating cabazitaxel's effectiveness in different lesion types, aside from its application in mCRPC, are currently underway, demonstrating the drug's extensive potential in pathology. For the treatment of individuals with metastatic castration-resistant prostate disease (mCRPC) whose illness has advanced on a docetaxel-containing regimen, capazitaxel and prednisone are approved together.
How Effective Is Cabazitaxel
Clinical studies have shown that the therapeutic effect of it on mCRPC patients has significantly prolonged survival and improved disease control rate. Its mechanism interferes with the microtubule dynamics of bad cells, affecting mitosis and causing cell death in swollen lesions. It is considered a microtubule inhibitor that can block the proliferation of bad cells and cause their death.
Among them, the famous TROPIC trial confirmed the advantages of it compared with mitoxantrone in treating mCRPC patients, showing significant survival prolongation and good tolerability. A crucial clinical experiment called TROPIC was created to assess the medication's safety and effectiveness in mCRPC patients. The study's results showed that among patients with mCRPC who had progressed after chemotherapy, those treated with it showed significant survival and disease control advantages. In addition, patients in the group also showed better quality of life and lower rates of adverse reactions compared with the control group. The results of the TROPIC trial provide clinically solid evidence for the use of it in treating mCRPC, making it one of the essential drug options for treating this stage of the disease.
A crucial research experiment called PROSELICA compares the safety and effectiveness of docetaxel for treating individuals with metastatic colorectal disease. Specifically, the PROSELICA trial compared XRP6258 and docetaxel in terms of survival, disease progression, quality of life, and incidence of adverse events in patients with mCRPC. Through this study, the medical community can obtain more comparative data and clinical effects of XRP6258 and docetaxel in the treatment of mCRPC patients.
A crucial clinical experiment called FIRSTANA aims to assess the safety and effectiveness of cisplatin plus XRP6258 in patients with advanced solid malignancies. The study was not specifically about prostate lesions but involved a trial to treat advanced solid bad cells. This trial aims to compare the clinical effects of XRP6258 and cisplatin in treating patients with advanced solid bad cells, including survival, disease progression, quality of life, and other factors. The FIRSTANA trial can provide performance and comparative data on the performance of these two drugs in treating patients with advanced solid bad cells, providing an essential clinical basis for medical practice.
What Are The Standard Doses Of Cabazitaxel
(1) The recommended dose of this product is based on the calculation of body surface area (BSA). Use 20 mg/m2 every three weeks, combined with oral prednisone 10 mg, and administer it every day during the treatment period of this product.
(2) For patients with high-risk clinical characteristics, primary prophylaxis with granulocyte colony-stimulating factor is recommended, and primary prevention with granulocyte colony-stimulating factor should be considered in all patients receiving a dose of 25 mg/m2.
(3) To lessen the likelihood and severity of an allergy, take the following drugs at least half an hour before each dosage:
①Antihistamines (dexchlorpheniramine 5mg, diphenhydramine 25mg, or equivalent antihistamines).
②Corticosteroids (dexamethasone 8mg or equivalent steroid).
③H2 antagonist.
2. Dose adjustment for adverse reactions
Dose Adjustment for Hepatic Impairment
(1) Mild liver function impairment (total bilirubin>1~<l.5x upper limit of normal (ULN) AST>1.5xULN): Administer 20mg/m2.
(2) Moderate liver function impairment (total bilirubin>1.5~<3xULN, AST=any): Based on the tolerability data of these patients, a dose of 15 mg/m2 of this product is given.
(3) Severe hepatic impairment (total bilirubin >3xULN): Contraindicated in patients with severe hepatic impairment.
Dose adjustment when using potent CYP3A inhibitors
The simultaneous use of drugs with strong CYP3A inhibitors (such as ketoconazole, itraconazole, and clarithromycin) may increase the plasma concentration of XRP6258. Avoid using this product at the same time as these drugs if the patient needs to use potent CYP3A inhibitors in combination. Consider reducing the dose of this product by 25%.
What Are The Adverse Effects Of Jevtana
This product's most common adverse reactions and laboratory abnormalities (10%) are neutropenia, anemia, diarrhea, nausea, fatigue, asthenia, vomiting, hematuria, constipation, decreased appetite, back pain, and abdominal pain.
Gastrointestinal adverse reactions
(1) Nausea, vomiting, and severe diarrhea may sometimes occur. Deaths related to diarrhea and electrolyte imbalance have occurred in randomized clinical trials. Severe diarrhea and electrolyte imbalance may require intensive measures. Preventing vomiting and providing patients with fluids and antidiarrhea as needed is recommended. Or antiemetics, if the patient develops grade ≥3 diarrhea, treatment may need to be delayed or the dose reduced.
(2) Patients treated with this product have reported gastrointestinal (GI) bleeding and perforation, intestinal obstruction, enterocolitis, and neutropenic enterocolitis, including fatal outcomes. Patients who have pelvic radiation therapy, adhesions, ulcers, and gastrointestinal bleeding, as well as those with neutropenia and concurrent use of nonsteroidal anti-inflammatory drugs, antiplatelet therapy, or anticoagulants, may also be at higher risk.
(3) Abdominal pain and tenderness, fever, persistent constipation, and diarrhea, with or without neutropenia, may be early manifestations of severe gastrointestinal toxicity.
(4) The incidence of gastrointestinal adverse reactions is higher in patients who have previously received radiotherapy. In the PROSELICA trial, 41% (297/732) of patients who received radiotherapy reported diarrhea and 27% (118/443) who did not receive radiotherapy reported diarrhea. Radiation therapy patients reported diarrhea. Patients who had previously undergone radiation therapy reported diarrhea at higher rates in those who got radiation therapy at a dose of 25 mg/m2 compared to those who received radiation therapy at a dose of 20 mg/m2.
Taboo
1. Neutrophil count ≤1500/mm3.
2. Severe hypersensitivity reactions to XRP6258 or other polysorbate 80 formulated drugs.
3. Severe liver function impairment (total bilirubin>3xULN).
If you want to know the chemotherapy manufacturer, you can contact Xi'an Sonwu. Click the email, and then you get high-quality cabazitaxel.
Email: sales@sonwu.com